These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 30702211)
1. In-vitro evaluation of a ciprofloxacin- and ivacaftor-coated sinus stent against Pseudomonas aeruginosa biofilms. Cho DY; Lim DJ; Mackey C; Weeks CG; Garcia JAP; Skinner D; Zhang S; McCormick J; Woodworth BA Int Forum Allergy Rhinol; 2019 May; 9(5):486-492. PubMed ID: 30702211 [TBL] [Abstract][Full Text] [Related]
2. Controlled delivery of ciprofloxacin and ivacaftor via sinus stent in a preclinical model of Pseudomonas sinusitis. Lim DJ; McCormick J; Skinner D; Zhang S; Elder JB; McLemore JG; Allen M; West JM; Grayson JW; Rowe SM; Woodworth BA; Cho DY Int Forum Allergy Rhinol; 2020 Apr; 10(4):481-488. PubMed ID: 31872532 [TBL] [Abstract][Full Text] [Related]
3. In-vitro evaluation of a ciprofloxacin and azithromycin sinus stent for Pseudomonas aeruginosa biofilms. Lim DJ; Skinner D; Mclemore J; Rivers N; Elder JB; Allen M; Koch C; West J; Zhang S; Thompson HM; McCormick JP; Grayson JW; Cho DY; Woodworth BA Int Forum Allergy Rhinol; 2020 Jan; 10(1):121-127. PubMed ID: 31692289 [TBL] [Abstract][Full Text] [Related]
4. Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against Pseudomonas aeruginosa. Cho DY; Lim DJ; Mackey C; Skinner D; Zhang S; McCormick J; Woodworth BA Am J Rhinol Allergy; 2019 Mar; 33(2):129-136. PubMed ID: 30585080 [TBL] [Abstract][Full Text] [Related]
5. l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Cho DY; Lim DJ; Mackey C; Weeks CG; Peña Garcia JA; Skinner D; Grayson JW; Hill HS; Alexander DK; Zhang S; Woodworth BA Int Forum Allergy Rhinol; 2018 May; 8(5):577-583. PubMed ID: 29412515 [TBL] [Abstract][Full Text] [Related]
6. Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis. Cho DY; Lim DJ; Mackey C; Skinner D; Weeks C; Gill GS; Hergenrother RW; Swords WE; Woodworth BA Int Forum Allergy Rhinol; 2018 Apr; 8(4):482-489. PubMed ID: 29334430 [TBL] [Abstract][Full Text] [Related]
7. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study. Millar BC; Rendall JC; Downey DG; Moore JE J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786 [TBL] [Abstract][Full Text] [Related]
8. Alginate lyase immobilized chitosan nanoparticles of ciprofloxacin for the improved antimicrobial activity against the biofilm associated mucoid P. aeruginosa infection in cystic fibrosis. Patel KK; Tripathi M; Pandey N; Agrawal AK; Gade S; Anjum MM; Tilak R; Singh S Int J Pharm; 2019 May; 563():30-42. PubMed ID: 30926526 [TBL] [Abstract][Full Text] [Related]
9. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. Baelo A; Levato R; Julián E; Crespo A; Astola J; Gavaldà J; Engel E; Mateos-Timoneda MA; Torrents E J Control Release; 2015 Jul; 209():150-8. PubMed ID: 25913364 [TBL] [Abstract][Full Text] [Related]
10. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059 [TBL] [Abstract][Full Text] [Related]
11. Ivacaftor restores delayed mucociliary transport caused by Pseudomonas aeruginosa-induced acquired cystic fibrosis transmembrane conductance regulator dysfunction in rabbit nasal epithelia. Cho DY; Zhang S; Skinner DF; Lim DJ; Banks C; Grayson JW; Tearney GJ; Rowe SM; Woodworth BA Int Forum Allergy Rhinol; 2022 May; 12(5):690-698. PubMed ID: 34704673 [TBL] [Abstract][Full Text] [Related]
12. Tolerance and pharmacokinetics of a ciprofloxacin-coated sinus stent in a preclinical model. Cho DY; Hoffman K; Skinner D; Mackey C; Lim DJ; Alexander GC; Bae CY; Han DK; Jun HW; Woodworth BA Int Forum Allergy Rhinol; 2017 Apr; 7(4):352-358. PubMed ID: 27992118 [TBL] [Abstract][Full Text] [Related]
13. Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents. Porsio B; Lentini L; Ungaro F; Di Leonardo A; Quaglia F; Giammona G; Cavallaro G Int J Pharm; 2020 May; 582():119304. PubMed ID: 32272167 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC; Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620 [TBL] [Abstract][Full Text] [Related]
16. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100 [TBL] [Abstract][Full Text] [Related]
17. Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients. Chang RYK; Das T; Manos J; Kutter E; Morales S; Chan HK AAPS J; 2019 Apr; 21(3):49. PubMed ID: 30949776 [TBL] [Abstract][Full Text] [Related]
18. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW; Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234 [TBL] [Abstract][Full Text] [Related]
19. Safety and Pharmacokinetics of a Ciprofloxacin and Azithromycin Stent for Chronic Rhinosinusitis. Lim DJ; Bicknell BT; Rivers N; Jones MP; Menon AJ; Kelly OJ; Skinner D; Zhang S; Woodworth BA; Cho DY Laryngoscope; 2024 Sep; 134(9):3953-3959. PubMed ID: 38563347 [TBL] [Abstract][Full Text] [Related]
20. PLGA Nanoparticles Formulations Loaded With Antibiotics Induce Sustained and Controlled Antibiotics Release for Prolonged Antibacterial Action Against MRSA, and Pseudomonas aeruginosa FRD1. Guevara A; Armknecht K; Kudary C; Nallathamby P Mil Med; 2024 Aug; 189(Suppl 3):230-238. PubMed ID: 39160825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]